Skip to main content
Have a personal or library account? Click to login
Potential of osteopontin in the management of epithelial ovarian cancer Cover

Potential of osteopontin in the management of epithelial ovarian cancer

Open Access
|Jan 2019

Figures & Tables

Figure 1

Receiver operating characteristic (ROC) curve for the diagnosis of ovarian cancer. The predictive performance of preoperative serum soluble osteopontin (sOPN) concentration (A) and ascites sOPN concentration (B). AUC = area under the curve

Figure 2

Kaplan-Meier survival curves. Overall survival (OS) according to preoperative soluble osteopontin (sOPN) concentrations in serum (A) and in ascites (B). Serum sOPN concentrations: group 1 ≤ 75.39 ng/ml (blue line) and group 2 > 75.39 ng/ml (green line). Ascites sOPN concentrations: group 1 ≤ 2729 ng/ml (blue line) and group 2 > 2729 ng/ml (green line).

Figure 3

Progression-free survival (PFS) according to preoperative soluble osteopontin (sOPN) concentrations in serum (A) and in ascites (B). Serum sOPN concentrations: group 1 ≤ 75.39 ng/ml (blue line) and group 2 > 75.39 ng/ml (green line). Ascites sOPN concentrations: group 1 ≤ 2729 ng/ml (blue line) and group 2 > 2729 ng/ml (green line).

Figure 4

Association of surgical outcome and soluble osteopontin (sOPN) concentrations in serum (A) and ascites (B) at primary operation. Group 1: patients with complete (R0) and optimal (R1) cytoreduction. Group 2: patients with suboptimal (R2) cytoreduction and unresectable disease. *p < 0.05

Figure 5

Correlation between serum cancer antigen 125 (CA125) normalisation after platinum-based chemotherapy and soluble osteopontin (sOPN) concentrations in preoperative serum (A) and ascites (B).

Figure 6

Comparison of soluble osteopontin (sOPN) concentrations in serum during treatment. Epithelial ovarian cancer (EOC) group - sOPN concentration: T0-preoperative, T1-after primary (debulking) surgery and T2–3 to 6 months after systemic chemotherapy. Control group (patients with benign gynaecological pathology) – sOPN concentrations: T0-preoperative and T2–3 to 6 months after surgery.

Figure 7

Association of tumour size and soluble osteopontin (sOPN) concentrations in preoperative serum (A) and ascites (B). Group 1: patients with tumour size ≤ 10 cm. Group 2: patients with tumour size > 10 cm. *p < 0.05

Characteristics of control patients

ParametersData
Control group
Number of patients34
Age (years, value ± SEM)41.97 ± 1.68
Age range (years)21-69
Elevated CA125 (U/mL)
n (%)0
Value (mean ± SEM)NA
sOPN (ng/mL)
Serum (mean ± SEM)28.12 ± 2.10
Peritoneal fluid (mean ± SEM)132.02 ± 7.85
Benign diagnosis, n (%)
Benign ovarian cyst6 (17 %)
Myoma of uterus21 (62 %)
Pelvic pain, sterilisation5 (15 %)
Preventive adnexectomy2 (6 %)
Peritoneal fluid (mL)
Volume (mean ± SEM)8.04 ± 1.22

Comparison between ovarian cancer patients’ characteristics who underwent primary debulking surgery and those considered candidates for neoadjuvant chemotherapy (= diagnostic laparoscopy as primary event)

Data
ParametersPrimary event: Debulking surgeryPrimary event: Diagnostic laparoscopy
Number of patients1318
Age (years, value ± SEM)57.61 ± 3.2762 ± 2.45
Age range (years)41-7645-85
Elevated CA125 (U/mL)
n (%)13 (100 %)18 (100 %)
Value (mean ± SEM)3936 ± 15683904 ± 1972
sOPN (ng/mL)
Serum (mean ± SEM)70.48 ± 9.95102 ± 11.53
Ascites (mean ± SEM)2154 ± 479.74515 ± 657.3
Histological type, n (%)
Serous10 (77 %)17 (94 %)
Endometrioid2 (15 %)1 (6 %)
Serous + clear cell1 (8 %)0 (0 %)
FIGO stage, n (%)
IIIB1 (8 %)0 (0 %)
IIIC11 (84 %)11 (61 %)
IV1 (8 %)7 (39 %)
Histological grade, n (%)
G10 (0 %)2 (11 %)
G25 (38 %)7 (39 %)
G38 (62 %)9 (50 %)
Ascites (mL)
Volume (mean ± SEM)1779 ± 728.43916 ± 614.7
Resection, n (%) *
R05 (38 %)9 (50 %)
R15 (38 %)1 (6 %)
R23 (24 %)0 (0 %)
Unresectable0 (0 %)8 (44 %)
DOI: https://doi.org/10.2478/raon-2019-0003 | Journal eISSN: 1581-3207 | Journal ISSN: 1318-2099
Language: English
Page range: 105 - 115
Submitted on: Sep 7, 2018
Accepted on: Dec 27, 2018
Published on: Jan 31, 2019
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year

© 2019 Katarina Cerne, Benjamin Hadzialjevic, Erik Skof, Ivan Verdenik, Borut Kobal, published by Association of Radiology and Oncology
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.